NMRA — Neumora Therapeutics Share Price
0.000.00%
Last trade - 00:00- $125.55m
- -$182.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.44 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.77% | ||
| Return on Equity | -64.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 3.57 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 22nd, 2019
- Public Since
- September 15th, 2023
- No. of Employees
- 110
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 161,747,922
- Address
- 490 Arsenal Way, Suite 200, WATERTOWN, 02472
- Web
- https://neumoratx.com/
- Phone
- +1 8577600900
- Contact
- Helen Rubinstein
- Auditors
- Ernst & Young LLP
Upcoming Events for NMRA
Q1 2025 Neumora Therapeutics Inc Earnings Call
Neumora Therapeutics Inc Annual Shareholders Meeting
Similar to NMRA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Neumora Therapeutics share price?
As of Today at 22:15 UTC, shares in Neumora Therapeutics are trading at $0.78. This share price information is delayed by 15 minutes.
How has the Neumora Therapeutics share price performed this year?
Shares in Neumora Therapeutics last closed at $0.78 and the price had moved by -91.58% over the past 365 days. In terms of relative price strength the Neumora Therapeutics share price has underperformed the S&P500 Index by -92.41% over the past year.
What are the analyst and broker recommendations for Neumora Therapeutics?
The overall consensus recommendation for Neumora Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neumora Therapeutics dividend yield?
Neumora Therapeutics does not currently pay a dividend.
Does Neumora Therapeutics pay a dividend?
Neumora Therapeutics does not currently pay a dividend.
When does Neumora Therapeutics next pay dividends?
Neumora Therapeutics does not currently pay a dividend.
How do I buy Neumora Therapeutics shares?
To buy shares in Neumora Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neumora Therapeutics?
As of the previous close price of $0.78, shares in Neumora Therapeutics had a market capitalisation of $125.55m.
Where are Neumora Therapeutics shares listed?
Here are the trading details for Neumora Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NMRA
What kind of share is Neumora Therapeutics?
Based on an overall assessment of its quality, value and momentum Neumora Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neumora Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Neumora Therapeutics is $5.67. That is 630.48% above the last closing price of $0.78.
Analysts covering Neumora Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.47 for the next financial year.
Find out moreWhat is the trend in the Neumora Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neumora Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -93.02%.
As of the last closing price of $0.78, shares in Neumora Therapeutics were trading -89.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neumora Therapeutics PE Ratio?
The Neumora Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neumora Therapeutics?
We do not have data on Neumora Therapeutics' directors